Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LIVINGSTON, NJ · NPI 1942260690
Verified facts
CMS Open Payments records show Samuel Dower, MD received $17.86 in general payments during 2025 across 1 reported records.
Medtronic, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.86 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.86 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1338 | 364 |
| Synthroid | Levothyroxine Sodium | 598 | 157 |
| Metformin Hcl Er | Metformin Hcl | 513 | 156 |
| Ozempic | Semaglutide | 374 | 79 |
| Metformin Hcl | Metformin Hcl | 356 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 97 |
| Glimepiride | Glimepiride | 299 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 79 |
| Mounjaro | Tirzepatide | 261 | 43 |
| Glipizide Er | Glipizide | 215 | 60 |
| Jardiance | Empagliflozin | 198 | 43 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 166 | 68 |
| Farxiga | Dapagliflozin Propanediol | 164 | 34 |
| Tradjenta | Linagliptin | 138 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 131 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 33 |
| Tresiba Flextouch U-100 | Insulin Degludec | 103 | 31 |
| Ezetimibe | Ezetimibe | 102 | 26 |
| Humalog Kwikpen U-100 | Insulin Lispro | 102 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 36 |
| Losartan Potassium | Losartan Potassium | 98 | 27 |
| Januvia | Sitagliptin Phosphate | 95 | 28 |
| Armour Thyroid | Thyroid,pork | 92 | 21 |
| Repaglinide | Repaglinide | 92 | 29 |
| Alprazolam | Alprazolam | 85 | 30 |
| Alendronate Sodium | Alendronate Sodium | 80 | 35 |
| Liothyronine Sodium | Liothyronine Sodium | 80 | 26 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 77 | 30 |
| Trulicity | Dulaglutide | 76 | 20 |
| Methimazole | Methimazole | 66 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 18 |
| Glipizide | Glipizide | 63 | 17 |
| Lisinopril | Lisinopril | 61 | 19 |
| Simvastatin | Simvastatin | 58 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 23 |
| Humalog | Insulin Lispro | 56 | 14 |
| Novolog Flexpen | Insulin Aspart | 56 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 15 |
| Amoxicillin | Amoxicillin | 42 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 42 | 15 |
| Gabapentin | Gabapentin | 41 | 11 |
| Ramipril | Ramipril | 41 | 11 |
| Omeprazole | Omeprazole | 38 | 12 |
| Rybelsus | Semaglutide | 38 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 36 | suppressed |
| Furosemide | Furosemide | 35 | 12 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Montelukast Sodium | Montelukast Sodium | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 13 |
| Atenolol | Atenolol | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 29 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 27 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 11 |
| Cephalexin | Cephalexin | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Tirosint | Levothyroxine Sodium | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Levoxyl | Levothyroxine Sodium | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Omnitrope | Somatropin | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Evista | Raloxifene Hcl | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Tresiba | Insulin Degludec | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Altace | Ramipril | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.86 · 1 records | Medtronic, Inc. | MINIMED 780G | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error